• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int Immunopharmacol . Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra

tetano

Editor, Senior Moderator
Int Immunopharmacol


. 2021 Jan 22;93:107407.
doi: 10.1016/j.intimp.2021.107407. Online ahead of print.
Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra


Esmaeil Mortaz[SUP] 1 [/SUP], Ali Bassir[SUP] 2 [/SUP], Neda Dalil Roofchayee[SUP] 3 [/SUP], Neda K Dezfuli[SUP] 3 [/SUP], Hamidreza Jamaati[SUP] 4 [/SUP], Payam Tabarsi[SUP] 5 [/SUP], Afshin Moniri[SUP] 5 [/SUP], Mitra Rezaei[SUP] 5 [/SUP], Payam Mehrian[SUP] 4 [/SUP], Mohammad Varahram[SUP] 4 [/SUP], Majid Marjani[SUP] 6 [/SUP], Sharon Mumby[SUP] 7 [/SUP], Ian M Adcock[SUP] 8 [/SUP]



Affiliations

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has infected 86,4 M patients and resulted in 1,86 M deaths worldwide. Severe COVID-19 patients have elevated blood levels of interleukin-6 (IL-6), IL-1β, tumor necrosis factor (TNF)α, IL-8 and interferon (IFN)γ.
Objective: To investigate the effect of antiviral treatment serum cytokines in severe COVID-19 patients.
Methods: Blood was obtained from 29 patients (aged 32-79 yr) with laboratory-confirmed COVID-19 upon admission and 7 days after antiviral (Favipiravir or Lopinavir/Ritonavir) treatment. Patients also received standard supportive treatment in this retrospective observational study. Chest computed tomography (CT) scans were evaluated to investigate lung manifestations of COVID-19. Serum was also obtained and cytokines levels were evaluated. 19 age- and gender-matched healthy controls were studied.
Results: Anti-viral therapy significantly reduced CT scan scores and the elevated serum levels of C-reactive protein (CRP) and lactate dehydrogenase (LDH). In contrast, serum levels of IL-6, IL-8 and IFNγ were elevated at baseline in COVID-19 subjects compared to healthy subjects with IL-6 (p = 0.006) and IL-8 (p = 0.011) levels being further elevated after antiviral therapy. IL-1β (p = 0.01) and TNFα (p = 0.069) levels were also enhanced after treatment but baseline levels were similar to those of healthy controls. These changes occurred irrespective of whether patients were admitted to the intensive care unit.
Conclusion: Antiviral treatments did not suppress the inflammatory phase of COVID-19 after 7 days treatment although CT, CRP and LDH suggest a decline in lung inflammation. There was limited evidence for a viral-mediated cytokine storm in these COVID-19 subjects.

Keywords: COVID-19; Cytokines storm; Flow cytometry; SARS-CoV-2.
 
Back
Top Bottom